|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACD |
Gene summary for ACD |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACD | Gene ID | 65057 |
| Gene name | ACD shelterin complex subunit and telomerase recruitment factor | |
| Gene Alias | PIP1 | |
| Cytomap | 16q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000723 | UniProtAcc | Q96AP0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 65057 | ACD | LZE4T | Human | Esophagus | ESCC | 4.48e-08 | 1.68e-01 | 0.0811 |
| 65057 | ACD | LZE7T | Human | Esophagus | ESCC | 8.51e-08 | 6.98e-01 | 0.0667 |
| 65057 | ACD | LZE8T | Human | Esophagus | ESCC | 8.61e-08 | 2.01e-01 | 0.067 |
| 65057 | ACD | LZE20T | Human | Esophagus | ESCC | 2.95e-03 | 8.92e-02 | 0.0662 |
| 65057 | ACD | LZE22T | Human | Esophagus | ESCC | 1.69e-03 | 4.51e-01 | 0.068 |
| 65057 | ACD | LZE24T | Human | Esophagus | ESCC | 2.87e-22 | 4.15e-01 | 0.0596 |
| 65057 | ACD | LZE21T | Human | Esophagus | ESCC | 1.76e-04 | 3.23e-01 | 0.0655 |
| 65057 | ACD | LZE6T | Human | Esophagus | ESCC | 1.33e-02 | 2.02e-01 | 0.0845 |
| 65057 | ACD | P1T-E | Human | Esophagus | ESCC | 7.31e-13 | 4.61e-01 | 0.0875 |
| 65057 | ACD | P2T-E | Human | Esophagus | ESCC | 1.06e-20 | 3.55e-01 | 0.1177 |
| 65057 | ACD | P4T-E | Human | Esophagus | ESCC | 5.28e-25 | 5.89e-01 | 0.1323 |
| 65057 | ACD | P5T-E | Human | Esophagus | ESCC | 6.63e-19 | 4.29e-01 | 0.1327 |
| 65057 | ACD | P8T-E | Human | Esophagus | ESCC | 8.85e-34 | 6.47e-01 | 0.0889 |
| 65057 | ACD | P9T-E | Human | Esophagus | ESCC | 2.92e-12 | 2.14e-01 | 0.1131 |
| 65057 | ACD | P10T-E | Human | Esophagus | ESCC | 3.78e-17 | 2.84e-01 | 0.116 |
| 65057 | ACD | P11T-E | Human | Esophagus | ESCC | 5.43e-12 | 4.38e-01 | 0.1426 |
| 65057 | ACD | P12T-E | Human | Esophagus | ESCC | 3.04e-18 | 2.56e-01 | 0.1122 |
| 65057 | ACD | P15T-E | Human | Esophagus | ESCC | 1.18e-16 | 3.27e-01 | 0.1149 |
| 65057 | ACD | P16T-E | Human | Esophagus | ESCC | 9.04e-21 | 3.48e-01 | 0.1153 |
| 65057 | ACD | P17T-E | Human | Esophagus | ESCC | 1.04e-14 | 5.93e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072521110 | Oral cavity | LP | purine-containing compound metabolic process | 130/4623 | 416/18723 | 1.30e-03 | 1.05e-02 | 130 |
| GO:000664311 | Oral cavity | LP | membrane lipid metabolic process | 69/4623 | 203/18723 | 1.77e-03 | 1.34e-02 | 69 |
| GO:004639018 | Oral cavity | LP | ribose phosphate biosynthetic process | 65/4623 | 190/18723 | 1.97e-03 | 1.47e-02 | 65 |
| GO:190129315 | Oral cavity | LP | nucleoside phosphate biosynthetic process | 84/4623 | 256/18723 | 1.98e-03 | 1.47e-02 | 84 |
| GO:0009259110 | Oral cavity | LP | ribonucleotide metabolic process | 120/4623 | 385/18723 | 2.15e-03 | 1.57e-02 | 120 |
| GO:000916515 | Oral cavity | LP | nucleotide biosynthetic process | 83/4623 | 254/18723 | 2.38e-03 | 1.71e-02 | 83 |
| GO:0006163110 | Oral cavity | LP | purine nucleotide metabolic process | 122/4623 | 396/18723 | 3.10e-03 | 2.11e-02 | 122 |
| GO:000679012 | Oral cavity | LP | sulfur compound metabolic process | 106/4623 | 339/18723 | 3.36e-03 | 2.25e-02 | 106 |
| GO:0009150110 | Oral cavity | LP | purine ribonucleotide metabolic process | 114/4623 | 368/18723 | 3.41e-03 | 2.28e-02 | 114 |
| GO:007252210 | Oral cavity | LP | purine-containing compound biosynthetic process | 66/4623 | 200/18723 | 4.84e-03 | 3.05e-02 | 66 |
| GO:00464671 | Oral cavity | LP | membrane lipid biosynthetic process | 49/4623 | 142/18723 | 5.44e-03 | 3.31e-02 | 49 |
| GO:000926018 | Oral cavity | LP | ribonucleotide biosynthetic process | 60/4623 | 182/18723 | 7.12e-03 | 4.00e-02 | 60 |
| GO:000616410 | Oral cavity | LP | purine nucleotide biosynthetic process | 62/4623 | 191/18723 | 9.12e-03 | 4.86e-02 | 62 |
| GO:001603218 | Prostate | BPH | viral process | 147/3107 | 415/18723 | 4.46e-21 | 5.52e-18 | 147 |
| GO:001905818 | Prostate | BPH | viral life cycle | 112/3107 | 317/18723 | 2.87e-16 | 5.54e-14 | 112 |
| GO:00072658 | Prostate | BPH | Ras protein signal transduction | 101/3107 | 337/18723 | 5.64e-10 | 2.79e-08 | 101 |
| GO:001907918 | Prostate | BPH | viral genome replication | 47/3107 | 131/18723 | 6.96e-08 | 1.83e-06 | 47 |
| GO:005079218 | Prostate | BPH | regulation of viral process | 53/3107 | 164/18723 | 5.22e-07 | 1.04e-05 | 53 |
| GO:00072499 | Prostate | BPH | I-kappaB kinase/NF-kappaB signaling | 79/3107 | 281/18723 | 7.61e-07 | 1.43e-05 | 79 |
| GO:004852415 | Prostate | BPH | positive regulation of viral process | 27/3107 | 65/18723 | 1.65e-06 | 2.78e-05 | 27 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACD | SNV | Missense_Mutation | c.229N>G | p.Pro77Ala | p.P77A | Q96AP0 | protein_coding | tolerated_low_confidence(0.84) | benign(0) | TCGA-E9-A1NA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| ACD | deletion | Frame_Shift_Del | novel | c.1359delA | p.Lys453AsnfsTer10 | p.K453Nfs*10 | Q96AP0 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| ACD | SNV | Missense_Mutation | c.874N>T | p.His292Tyr | p.H292Y | Q96AP0 | protein_coding | deleterious(0.01) | benign(0.091) | TCGA-EK-A2RA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ACD | SNV | Missense_Mutation | c.1006N>A | p.Glu336Lys | p.E336K | Q96AP0 | protein_coding | tolerated(0.07) | benign(0.078) | TCGA-FU-A5XV-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ACD | insertion | Frame_Shift_Ins | novel | c.1206_1207insTGCTCAC | p.Pro403CysfsTer38 | p.P403Cfs*38 | Q96AP0 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
| ACD | SNV | Missense_Mutation | rs747913250 | c.1405N>T | p.Arg469Trp | p.R469W | Q96AP0 | protein_coding | tolerated(0.25) | benign(0) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ACD | SNV | Missense_Mutation | rs762262197 | c.1261C>T | p.Arg421Cys | p.R421C | Q96AP0 | protein_coding | tolerated(0.19) | benign(0.057) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACD | SNV | Missense_Mutation | c.469G>A | p.Val157Met | p.V157M | Q96AP0 | protein_coding | tolerated(0.07) | probably_damaging(0.957) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ACD | SNV | Missense_Mutation | c.1217N>A | p.Cys406Tyr | p.C406Y | Q96AP0 | protein_coding | deleterious(0.04) | possibly_damaging(0.867) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ACD | SNV | Missense_Mutation | rs781117606 | c.1409N>T | p.Pro470Leu | p.P470L | Q96AP0 | protein_coding | tolerated(0.09) | benign(0) | TCGA-G4-6306-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |